Thursday, September 27 16:24:23
The U.S. Food and Drug Administration today approved a new drug for advanced colon cancer developed by Bayer AG a month ahead of the agency's expected action date for a decision on the medicine.
The drug, to be sold under the brand name Stivarga, was approved to treat colon cancer that has progressed after prior treatment or has spread to other parts of the body, the agency said.
In pivotal clinical trials, Stivarga -- known chemically as regorafenib -- helped patients live on average 1.4 months longer than those who received standard treatment without the Bayer drug. (C ) Reuters